Skip to main content

Kronos Bio Inc(KRON-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results

Globe Newswire - Thu Feb 24, 2022

Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza